Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist

With competition on the way, Novo Nordisk gained access to a conjugation technology from Ascendis that will help the pharma develop a once-monthly GLP-1R agonist for obesity and Type II diabetes.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) agreed to pay $100 million up front plus potential milestones to use the TransCon transient conjugation technology of  Ascendis Pharma A/S (NASDAQ:ASND)...